Timothy Campbell

Statistics

Publications

Citations

7.4K

H-Index

Active since

2004

Affiliations

Bristol-Myers Squibb (United States)(Current)

Dana-Farber Cancer Institute

Clinica Universidad de Navarra

Bluebird Bio (United States)

Massachusetts General Hospital

Timothy Campbell is an author at Bristol-Myers Squibb (United States) specializing in multiple myeloma, cancer immunotherapy, and multiple myeloma therapy.

ORCID

Publications per year

2004–2023

Publications

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text

Medicine, Hematology, Oncology +17

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje, Jesús G. Berdeja, Yi Lin et al. · New England Journal of Medicine · 2019 · 1.7K citations · Full text

Medicine, Immunology, Oncology +17

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Hal E. Broxmeyer, Christie M. Orschell, D. Wade Clapp et al. · The Journal of Experimental Medicine · 2005 · 1.1K citations · Full text

Medicine, Immunology, Pharmacology +16

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Mehmet Samur, Mariateresa Fulciniti, Anıl Aktaş Samur et al. · Nature Communications · 2021 · 409 citations · Full text

Life Sciences, Genetics, Molecular Biology +15

Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis

Hal E. Broxmeyer, Jonathan Hoggatt, Heather A. O’Leary et al. · Nature Medicine · 2012 · 224 citations

Life Sciences, Hematology, Molecular Biology +13

1–5 of 40